ストックスクリーナーアプリを入手
3.06
3.03%
0.09
プレマーケット:
3.04
-0.02
-0.65%
前日終値:
$2.97
開ける：
$3
24時間の取引高:
3.69M
Relative Volume:
1.37
時価総額：
$903.82M
収益：
$38.03M
当期純損益:
$-146.40M
株価収益率:
-5.8846
EPS:
-0.52
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
+10.47%
1か月 パフォーマンス:
+7.37%
6か月 パフォーマンス:
+3.03%
1年 パフォーマンス:
-41.60%
1日の値動き範囲:
$2.96
$3.14
1週間の範囲:
$2.81
$3.14
52週間の値動き範囲:
$2.335
$5.62
Abcellera Biologics Inc Stock (ABCL) Company Profile
ABCL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.06 | 903.82M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29% - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7%What's Next? - MarketBeat
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5%What's Next? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.7%Here's Why - MarketBeat
Geode Capital Management LLC Has $295,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - sharewise
AbCellera and AbbVie expand oncology collaboration - Investing.com
AbCellera and AbbVie expand oncology collaboration By Investing.com - Investing.com South Africa
AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $4.00 by Analysts at KeyCorp - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9%What's Next? - MarketBeat
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? - Insider Monkey
12 Best Canadian Penny Stocks to Buy According to Analysts - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7.2%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6%What's Next? - MarketBeat
AbCellera Biologics: Still A Concept Stock (NASDAQ:ABCL) - Seeking Alpha
Is AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth? - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Trading Up 3.3%Should You Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpHere's What Happened - MarketBeat
Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (FRA:8QQ) Price-to-Owner-Earnings : (As of Dec. 07, 2024) - GuruFocus.com
PDT Partners LLC Sells 173,884 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year By Investing.com - Investing.com Canada
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year - Investing.com India
AbCellera Biologics (FRA:8QQ) Degree of Operating Leverage : -1.44 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Debt : $3.95 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Pre-Tax Income : $-202.17 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Capex-to-Revenue : 2.85 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Buildings And Improvements : $66.92 Mil (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
US Penny Stocks To Consider In November 2024 - Simply Wall St
ABCL (AbCellera Biologics) Revenue per Share : $0.11 (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Change In Receivables : $-64.70 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Debt-to-Equity : 0.07 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Owner Earnings per Share (TTM) : -0.61 (As of Sep. 2024) - GuruFocus.com
AbCellera to Present at Upcoming Investor Conferences in December and January - Devon Dispatch
AbCellera to Present at Major Healthcare Conferences: Piper Sandler and JPM 2024-25 - StockTitan
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):